– USA, MA – Rapid Micro Biosystems, Inc. (Nasdaq: RPID) today announced the appointment of Inese Lowenstein to its Board of Directors.
“We are very excited to welcome Inese, an experienced Life Science business leader in the STEM field to our board of directors. She has held leadership positions at Danaher Corporation, SCIEX, Merck KGaA, and EMD Millipore and has a track record of delivering strong results by building highly performing teams and driving commercial execution, customer-focused innovation, and strategic M&A. Her passion for creating engaged and inclusive corporate culture and her deep expertise in the life sciences industry will be invaluable as we pursue our vision of becoming the trusted standard in the global microbial quality control marketplace,” said CEO, Robert Spignesi. “
About Inese Lowenstei
Inese Lowenstei has been at Danaher for five years, currently serving in a part time role as Senior Talent Advisor. Prior to her current role, she was President of SCIEX, a Danaher company, where she enhanced the organization’s innovation and commercial execution capabilities. Inese Lowenstein has over 20 years of cross-industry and international experience and a strong leadership background in sales, marketing, product management and general management. Prior to prior to joining Danaher, she held roles of increasing responsibility at Merck KGaA and EMD Millipore, most recently as EVP, Head of Display Materials Business Unit.
“I am honored to join the board at Rapid Micro Biosystems and excited to be part of a growing team developing technology solutions that support the quality manufacturing of pharmaceutical products,” said Inese Lowenstein.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct System automates and modernizes the antiquated, manual microbial quality control testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct System brings the quality control lab to the manufacturing floor, unlocking the power of in-line/at-the-line MQC automation to deliver faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making, that customers rely on to ensure safe and consistent supply of important healthcare products.
The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands.
For more information : https://www.rapidmicrobio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.